From the Department of Anesthesiology, Perioperative and Pain Medicine and Program in Cellular and Molecular Medicine, Boston Children's Hospital; Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts; Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan.
Anesth Analg. 2013 Oct;117(4):803-811. doi: 10.1213/ANE.0b013e3182a00ae0. Epub 2013 Aug 19.
We previously demonstrated that propofol interacted with the leukocyte adhesion molecule leukocyte function-associated antigen-1 (LFA-1) and inhibited the production of interleukin-2 via LFA-1 in a dependent manner. However, the binding site(s) of propofol on LFA-1 remains unknown.
First, the inhibition of LFA-1's ligand binding by propofol was confirmed in an enzyme-linked immunosorbent assay (ELISA) ELISA-type assay. The binding site of propofol on LFA-1 was probed with a photolabeling experiment using a photoactivatable propofol analog called azi-propofol-m. The adducted residues of LFA-1 by this compound were determined using liquid chromatography-mass spectrometry. In addition, the binding of propofol to the ligand-binding domain of LFA-1 was examined using 1-aminoanthracene (1-AMA) displacement assay. Furthermore, the binding site(s) of 1-AMA and propofol on LFA-1 was studied using the docking program GLIDE.
We demonstrated that propofol impaired the binding of LFA-1 to its ligand intercellular adhesion molecule-1. The photolabeling experiment demonstrated that the adducted residues were localized in the allosteric cavity of the ligand-binding domain of LFA-1 called "lovastatin site." The shift of fluorescence spectra was observed when 1-AMA was coincubated with the low-affinity conformer of LFA-1 ligand-binding domain (wild-type [WT] αL I domain), not with the high-affinity conformer, suggesting that 1-AMA bound only to WT αL I domain. In the 1-AMA displacement assay, propofol decreased 1-AMA fluorescence signal (at 520 nm), suggesting that propofol competed with 1-AMA and bound to the WT αL I domain. The docking simulation demonstrated that both 1-AMA and propofol bound to the lovastatin site, which agreed with the photolabeling experiment.
We demonstrated that propofol bound to the lovastatin site in LFA-1. Previously we showed that the volatile anesthetics isoflurane and sevoflurane bound to this site. Taken together, the lovastatin site is an example of the common binding sites for anesthetics currently used clinically.
我们之前的研究表明,异丙酚通过白细胞功能相关抗原-1(LFA-1)与白细胞黏附分子相互作用,并依赖于 LFA-1 抑制白细胞介素-2 的产生。然而,异丙酚在 LFA-1 上的结合部位仍不清楚。
首先,通过酶联免疫吸附试验(ELISA)型试验证实异丙酚对 LFA-1 配体结合的抑制作用。使用光活化异丙酚类似物 azi-propofol-m 进行光标记实验,以探测异丙酚在 LFA-1 上的结合部位。使用液相色谱-质谱法确定该化合物与 LFA-1 结合的残基。此外,通过 1-氨基蒽(1-AMA)置换试验检查异丙酚与 LFA-1 配体结合域的结合。此外,使用对接程序 GLIDE 研究 1-AMA 和异丙酚在 LFA-1 上的结合部位。
我们证明异丙酚损害了 LFA-1 与其配体细胞间黏附分子-1 的结合。光标记实验表明,结合的残基定位于 LFA-1 配体结合域的变构腔中,称为“洛伐他汀位点”。当 1-AMA 与 LFA-1 配体结合域的低亲和力构象(野生型[WT]αL I 结构域)共孵育时,观察到荧光光谱的位移,而与高亲和力构象没有位移,提示 1-AMA 仅与 WTαL I 结构域结合。在 1-AMA 置换试验中,异丙酚降低了 1-AMA 的荧光信号(在 520nm 处),提示异丙酚与 1-AMA 竞争并与 WTαL I 结构域结合。对接模拟表明,1-AMA 和异丙酚均与洛伐他汀位点结合,这与光标记实验一致。
我们证明异丙酚与 LFA-1 中的洛伐他汀位点结合。我们之前的研究表明,挥发性麻醉剂异氟烷和七氟烷结合在这个位点上。总之,洛伐他汀位点是目前临床使用的麻醉剂的共同结合位点的一个例子。